{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:14Z","timestamp":1792801094587,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Royal Australian and New Zealand College of Radiologists","award":["2014\/RANZCR\/006"],"award-info":[{"award-number":["2014\/RANZCR\/006"]}],"id":[{"id":"https:\/\/ror.org\/01x7kw596","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hunter Translational Cancer Research Grant","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13014-019-1342-9","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T09:02:27Z","timestamp":1565082147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["FDG-PET parameters predict for recurrence in anal cancer \u2013 results from a prospective, multicentre clinical trial"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-5383","authenticated-orcid":false,"given":"Michael Peter","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ur","family":"Metser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Capp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Oldmeadow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"issue":"3","key":"1342_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jnci\/djs491","volume":"105","author":"A Jemal","year":"2013","unstructured":"Jemal A, Simard EP, Dorell C, Noone A-M, Markowitz LE, Kohler B, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175\u2013201.","journal-title":"J Natl Cancer Inst"},{"key":"1342_CR2","volume-title":"Anal carcinoma (version 2.2018)","author":"National Comprehensive Cancer Network","year":"2018","unstructured":"National Comprehensive Cancer Network. Anal carcinoma (version 2.2018). 2018. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf\n                    \n                  ."},{"issue":"3","key":"1342_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","volume":"111","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO\u2013ESSO\u2013ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330\u20139 Elsevier Ireland Ltd.","journal-title":"Radiother Oncol"},{"issue":"11","key":"1342_CR4","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","volume":"22","author":"M Jones","year":"2015","unstructured":"Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(11):3574\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1342_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijrobp.2007.09.005","volume":"71","author":"JK Schwarz","year":"2008","unstructured":"Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET\/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):180\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1342_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.radonc.2008.04.003","volume":"87","author":"BT Nguyen","year":"2008","unstructured":"Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol. 2008;87(3):376\u201382 Elsevier Ireland Ltd.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1342_CR7","first-page":"498","volume":"105","author":"FL Day","year":"2011","unstructured":"Day FL, Link E, Ngan S, Leong T, Moodie K, Lynch C, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Nat Publ Group. 2011;105(4):498\u2013504.","journal-title":"Nat Publ Group"},{"issue":"9","key":"1342_CR8","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.2967\/jnumed.116.185280","volume":"58","author":"C Houard","year":"2017","unstructured":"Houard C, Pinaquy J-B, Mesguich C, Henriques de Figueiredo B, Cazeau A-L, Allard J-B, et al. Role of 18F-FDG PET\/CT in posttreatment evaluation of anal carcinoma. J Nucl Med. 2017;58(9):1414\u201320.","journal-title":"J Nucl Med"},{"issue":"5","key":"1342_CR9","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/j.prro.2016.01.004","volume":"6","author":"KE Goldman","year":"2016","unstructured":"Goldman KE, White EC, Rao AR, Kaptein JS, Lien WW. Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma. Pract Radiat Oncol. 2016;6(5):e149\u201354 Elsevier.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"1342_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.radonc.2010.02.019","volume":"95","author":"EA Kidd","year":"2010","unstructured":"Kidd EA, Dehdashti F, Siegel BA, Grigsby PW. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol. 2010;95(3):288\u201391 Elsevier Ireland Ltd.","journal-title":"Radiother Oncol"},{"key":"1342_CR11","first-page":"1","volume-title":"Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. La radiologia medica","author":"L Deantonio","year":"2015","unstructured":"Deantonio L, Milia ME, Cena T, Sacchetti G, Perotti C, Brambilla M, et al. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. La radiologia medica. 7th ed. Springer Milan; 2015;121(1):1\u20136.","edition":"7"},{"issue":"1","key":"1342_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.112.109470","volume":"54","author":"JG Bazan","year":"2013","unstructured":"Bazan JG, Koong AC, Kapp DS, Quon A, Graves EE, Loo BW, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013;54(1):27\u201332.","journal-title":"J Nucl Med"},{"issue":"1","key":"1342_CR13","first-page":"1","volume":"44","author":"M Gauth\u00e9","year":"2016","unstructured":"Gauth\u00e9 M, Richard-Molard M, Fayard J, Alberini J-L, Cacheux W, Li\u00e8vre A. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET\/CT in anal canal cancer. Eur J Nucl Med Mol Imaging. 2016;44(1):1\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1342_CR14","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.ejrad.2016.05.009","volume":"85","author":"SM Shali","year":"2016","unstructured":"Shali SM, Schmitt V, Behrendt FF, Winz OH, Heinzel A, Mottaghy FM, et al. Metabolic tumour volume of anal carcinoma on 18FDG PET\/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. Eur J Radiol. 2016;85(8):1390\u20134 Elsevier Ireland Ltd.","journal-title":"Eur J Radiol"},{"issue":"1","key":"1342_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12885-015-1244-7","volume":"15","author":"M Jones","year":"2015","unstructured":"Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, et al. Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer. 2015;15(1):281.","journal-title":"BMC Cancer"},{"issue":"5","key":"1342_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","volume":"83","author":"M Ng","year":"2012","unstructured":"Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455\u201362 Elsevier.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1342_CR17","first-page":"1):1","volume":"52","author":"H-J Im","year":"2017","unstructured":"Im H-J, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging. 2017;52:1):1\u201311.","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"1342_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1245\/s10434-009-0719-7","volume":"17","author":"SH Hyun","year":"2009","unstructured":"Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-Fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2009;17(1):115\u201322.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1342_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-013-2530-8","volume":"41","author":"SH Hyun","year":"2014","unstructured":"Hyun SH, Ahn HK, Kim H, Ahn M-J, Park K, Ahn YC, et al. Volume-based assessment by (18) F-FDG PET\/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):50\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1342_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1148\/radiol.12111148","volume":"264","author":"HHW Chen","year":"2012","unstructured":"Chen HHW, Chiu N-T, Su W-C, Guo H-R, Lee B-F. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET\/CT in non\u2013small cell lung cancer. RY. 2012;264(2):559\u201366.","journal-title":"RY"},{"issue":"1","key":"1342_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13139-010-0062-8","volume":"45","author":"BS Kim","year":"2010","unstructured":"Kim BS, Kim IJ, Kim S-J, Nam H-Y, Pak KJ, Kim K, et al. The prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: measured by F-18 FDG PET\/CT. Nucl Med Mol Imaging. 2010;45(1):36\u201342 Springer-Verlag.","journal-title":"Nucl Med Mol Imaging"},{"issue":"10","key":"1342_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2967\/jnumed.111.101402","volume":"53","author":"R Lim","year":"2012","unstructured":"Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET\/CT metabolic tumor volume and Total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53(10):1506\u201313.","journal-title":"J Nucl Med"},{"issue":"1","key":"1342_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0167-8140(01)00404-2","volume":"61","author":"RJ Myerson","year":"2001","unstructured":"Myerson RJ, Kong F, Birnbaum EH, Fleshman JW, Kodner IJ, Picus J, et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol. 2001;61(1):15\u201322.","journal-title":"Radiother Oncol"},{"issue":"7","key":"1342_CR24","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s10350-004-0548-5","volume":"47","author":"RP Akbari","year":"2004","unstructured":"Akbari RP, Paty PB, Guillem JG, Weiser MR, Temple LK, Minsky BD, et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum. 2004;47(7):1136\u201344.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"1342_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10350-007-9125-z","volume":"51","author":"R Roohipour","year":"2008","unstructured":"Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008;51(2):147\u201353.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"1342_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijrobp.2011.10.048","volume":"84","author":"M Mistrangelo","year":"2012","unstructured":"Mistrangelo M, Pelosi E, Bell\u00f2 M, Ricardi U, Milanesi E, Cassoni P, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):66\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1342_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.adro.2017.04.007","volume":"2","author":"ML Cardenas","year":"2017","unstructured":"Cardenas ML, Spencer CR, Markovina S, DeWees TA, Mazur TR, Weiner AA, et al. Quantitative FDG-PET\/CT predicts local recurrence and survival for squamous cell carcinoma of the anus. Adv Radiat Oncol. 2017;2(3):281\u20137.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"1342_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5260305","volume":"2017","author":"CL Wright","year":"2017","unstructured":"Wright CL, Binzel K, Zhang J, Knopp MV. Advanced functional tumor imaging and precision nuclear medicine enabled by digital PET technologies. Contrast Media Mol Imaging. 2017;2017(5):1\u20137 Hindawi.","journal-title":"Contrast Media Mol Imaging"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1342-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1342-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1342-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T19:07:31Z","timestamp":1596568051000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1342-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1342-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"15 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Hunter New England Human Research Ethics Committee (reference: HREC\/12\/HNE\/408).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}